Sarcoidosis: Immunopathogenetic concepts and their clinical application

European Respiratory Journal

Volumn 12, Issue 3, 1998, Pages 716-738

  Muller Quernheim J ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Alveolar macrophage; Cytokines; Prednisolone; Sarcoidosis; T lymphocyte

Indexed keywords

B7 ANTIGEN; BIOCHEMICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOXIFYLLINE; PREDNISOLONE; RANTES; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

CYTOKINE PRODUCTION; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; GRANULOMA; HEREDITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; IMMUNOPATHOGENESIS; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MACROPHAGE; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS; SERODIAGNOSIS; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; ANIMALS; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; SARCOIDOSIS; T-LYMPHOCYTES;

EID: 0031661150     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12030716     Document Type: Review

References (305)

1. Newman LS, Rose CS, Maier LA. Medical progress: sarcoidosis. N Engl J Med 1997; 336: 1224-1234.
2. Myrvik Q, Leake E, Farris B. Studies on pulmonary alveolar macrophages from the normal rabbit: a technique to procure them in a high state of purity. J Immunol 1961; 86: 128-136.
3. Reynolds H. State of the art: bronchoalveolar lavage. Am Rev Respir Dis 1987; 135: 250-263.
4. Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981; 305: 429-434.
5. Teirstein AS, Lesser M. Worldwide distribution and epidemiology of sarcoidosis. In: Fanburg B, ed. Sarcoidosis and Other Granulomatous Diseases of the Lung, Basel, Dekker, 1983; pp. 101-134.
6. Löfgren S. Primary pulmonary sarcoidosis. Acta Med Scand 1953; 145: 424-465.
7. Veien NK. Cutaneous sarcoidosis: prognosis and treatment. Clin Dermatol 1986; 4: 75-87.
8. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in health maintenance organization. Am J Epidemol 1997; 145: 234-241.
9. Viskum K, Vestbo J. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. Eur Respir J 1993; 6: 349-353.
10. Vestbo J, Viskum K. Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis. Sarcoidosis 1994; 11: 123-125.
11. Maná J, Badrinas F. Prognosis of sarcoidosis. An unresolved issue. Sarcoidosis 1992; 9: 15-20.
12. Israel H, Karlin P, Menduke H, DeLisser O. Factors affecting outcome of sarcoidosis: influence of race, extrathoracic involvement, and initial radiologic lung lesions. Ann NY Acad Sci 1986; 465: 609-618.
13. Olive K, Kataria Y. Cutaneous manifestations of sarcoidosis. Relationships to other organ system involvement, abnormal laboratory measurements, and disease course. Arch Intern Med 1985; 145: 1811-1814.
14. Keller AZ. Hospital, age, racial, occupational, geographical, clinical and survivorship characteristics in the epidemiology of sarcoidosis. Am J Epidemiol 1971; 94: 222-230.
15. Rybicki BA, Harrington D, Major M, et al. Heterogeneity of familial risk in sarcoidosis. Genet Epidemiol 1996; 13: 23-33.
16. Jörgensen G. Die Genetik der Sarkoidose. Acta Med Scand 1964; 425: Suppl. 209-212.
17. Odum N, Milman N, Jakobsen BR, Georgsen J, Svejgaard A. HLA class II (DR, DQ, DP) in patients with sarcoidosis: evidence of an increased frequency of DRw6. Exp Clin Immunogenet 1991; 8: 227-232.
18. Martinetti M, Tinelli C, Kolek V, et al. "The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995; 152: 557-564.
19. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell 1996; 85: 311-318.
20. Hugot JP, Laurent P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1997; 379: 821-823.
21. Rybicki BA, Maliarik MJ, Major M, Popovich J Jr, Iannuzzi MC. Genetics of sarcoidosis. Clin Chest Med 1997; 18: 707-717.
22. Wordsworth P. Genes and arthritis. Br Med Bull 1995; 51: 249-266.
23. Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347: 1212-1217.
24. Risch N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet 1987; 40: 1-14.
25. Hochberg MC. The application of genetic epidemiology to systemic lupus erythematosus. J Rheumatol 1987; 14: 867-869.
26. Gregory WL, Bassendine MF. Genetic factors in primary biliary cirrhosis. J Hepatol 1994; 20: 689-692.
27. Tromp G, Kuivaniemi H, Raphael S, et al. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16. Am J Hum Genet 1996; 59: 1097-1107.
28. Kirsten D. Sarkoidose in Deutschland. Pneumologie 1995; 49: 378-382.
29. Richeldi L, Sorrentino R, Saltini C. HLA-DPB 1 glutamate 69: a genetic marker of beryllium disease. Science 1993; 262: 242-244.
30. Saltini C, Sorrentino R, Richeldi L, Luisetti M, Bisetti A. Role of the HLA-DP gene in susceptibility to lung granulomas. Sarcoidosis 1993; 10: 171-172.
31. Foley P, Lympany P, Puscinska E, et al. HLA-DPB1 and TAP1 polymorphisms in sarcoidosis. Chest 1997; 111: Suppl, 73S.
32. Lympany PA, Petrek M, Southcott AM, Newman Taylor AJ, Welsh KI, du Bois RM. HLA-DPB polymorphisms: Glu 69 association with sarcoidosis. Eur J Immunogenet 1996; 23: 353-359.
33. Schürmann M, Bein G, Kirsten D, Schlaak M, Müller-Quernheim J, Schwinger E. HLA-DQB1 and HLA-DPB1 senotypes in familial sarcoidosis. Respir Med 1998; 92: 649-652.
34. Furuya K, Yamaguchi E, Itoh A, et al. Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax 1996; 51: 777-780.
35. Arbustini E, Grasso M, Leo G, et al. Polymorphism of angiotensin-converting enyme gene in sarcoidosis. Am J Respir Crit Care Med 1996; 153: 851-854.
36. Sharma P, Smith I, Maguire G, Stewart S, Shneerson J, Brown MJ. Clinical value of ACE genotyping in diagnosis of sarcoidosis. Lancet 1997; 349: 1602-1603.
37. Tomita H, Ina Y, Sugiura Y, et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med 1997; 156: 255-259.
38. Schürmann M, du Bois RM, Reichel P, et al. Genetic studies in familial sarcoidosis. Am J Respir Crit Care Med 1988; 157: A30.
39. Gilbert S, Steinbrech DS, Landas SK, Hunninghake GW. Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease Am Rev Respir Dis 1993; 148: 483-486.
40. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Müller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156: 1586-1592.
41. Redondo P, Espana A, Sola J, Rocha E, Quintanilla E. Sarcoid-like granulomas secondary to herpes simplex virus infection. Dermatology 1992; 185: 137-139.
42. Kuwano K, Nomoto Y, Kunitake R, et al. Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction. Eur Respir J 1997; 10: 1445-1449.
43. Di Alberti L, Piattelli A, Artese L, et al. Human herpesvirus 8 variants in sarcoid tissues. Lancet 1997; 350: 1655-1661.
44. Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 1996; 2: 918-924.
45. Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996; 335: 233-241.
46. Kikuta H, Itakura O, Ariga T, Kobayashi K. Detection of human herpesvirus 8 DNA sequences in peripheral blood mononuclear cells of children. J Med Virol 1997; 53: 81-84.
47. Rettig MB, Ma HJ, Vescio RA, et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997; 276: 1851-1854.
48. Monini P, de Lellis L, Fabris M, Rigolin P, Cassai E. Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. N Engl J Med 1996; 334: 1168-1172.
49. Davis DA, Humphrey RW, Newcomb FM, et al. Detection of serum antibodies to a Kaposi's sarcoma-associated herpesvirus-specific peptide. J Infect Dis 1997; 175: 1071-1079.
50. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996; 348: 858-861.
51. Di Alberti L, Ngui SL, Porter SR, et al. Presence of human herpesvirus 8 variants in the oral tissues of human immunodeficiency virus-infected persons. J Infect Dis 1997; 175: 703-707.
52. Popper HH, Klemen H, Hoefler G, Winter E. Presence of mycobacterial DNA in sarcoidosis. Hum Pathol 1997; 28: 796-800.
53. Vanek J, Schwarz J. Demonstration of acid-fast rods in sarcoidosis. Am Rev Respir Dis 1970; 101: 395-400.
54. Almenoff PL, Johnson A, Lesser M, Mattman LH. Growth of acid-fast L forms from the blood of patients with sarcoidosis. Thorax 1996; 51: 530-533.
55. Mitchell I, Turk J, Mitchell D. Detection of mycobacterial rRNA in sarcoidosis with liquid-phase hybridisation. Lancet 1992; 339: 1015-1017.
56. Saboor S, Johnson N, McFadden J. Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet 1992; 339: 1012-1015.
57. Bocart D, Lecossier D, de Lassence A, Valeyre D, Battesti J-P, Hance AJ. A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Am Rev Respir Dis 1992; 145: 1142-1148.
58. Gerdes J, Richter E, Rüsch-Gerdes S, et al. Mycobacterial nucleic acids in sarcoid lesions. Lancet 1992; 339: 1536-1537.
59. Ghossein RA, Ross DG, Salomon RN, Rabson AR. A search for mycobacterial DNA in sarcoidosis using the polymerase chain reaction. Am J Clin Pathol 1994; 101: 733-737.
60. Vokurka M, Lecossier D, du Bois RM, et al. Absence of DNA from mycobacteria of the M. tuberculosis complex in sarcoidosis. Am J Respir Crit Care Med 1997; 156: 1000-1003.
61. Badrinas F, Morera J, Fité E, Plasencia A. Seasonal clustering of sarcoidosis. Lancet 1989; 334: 455-456.
62. Parkes S, Baker SdC, Bourdillon R, Murray C, Rakshit M. Epidemiology of sarcoidosis in the Isle of Man -1: a case controlled study. Thorax 1987; 42: 420-426.
63. Kern D, Neill M, Wrenn D, Varone J. Investigation of a unique time-space cluster of sarcoidosis in firefighters. Am Rev Respir Dis 1993; 148: 974-980.
64. Edmondstone W. Sarcoidosis in nurses: is there an association? Thorax 1988; 43: 342-343.
65. Burke W, Keogh A, Maloney P, Delprado W, Bryant D, Spratt P. Transmission of sarcoidosis via cardiac transplantation. Lancet 1990; 336: 1579.
66. Hua Bing, Li Qing-di, Wang Fu-min, Ai Cheng-xu, Luo Wei-ci. Borrelia burgdorferi infection may be the cause of sarcoidosis. Chin Med J 1992; 105: 560-563.
67. Jacob F. Could Borrelia burgdorferi be a causal agent of sarcoidosis. Med Hypotheses 1989; 30: 241-243.
68. Martens H, Zöllner B, Zissel G, Burdon D, Schlaak M, Müller-Quernheim J. Anti-Borrelia burgdorferi immunoglobulin seroprevalence in pulmonary sarcoidosis. Eur Respir J 1997; 10: 1356-1358.
69. Puolakkainen M, Campbell LA, Kuo CC, Leinonen M, Grönhasen-Riska C, Saikku P. Serological response to Chlamydia pneumoniae in patients with sarcoidosis. J Infection 1996; 33: 199-203.
70. Blasi F, Rizzato G, Gambacorta M, et al. Failure to detect the presence of Chlamydia pneumoniae in sarcoid pathology specimens. Eur Respir J 1997; 10: 2609-2611.
71. Haahr S, Munch M, Christensen T, Møller-Larsen A, Hvas J. Cluster of multiple sclerosis patients from Danish community. Lancet 1997; 349: 923.
72. Johnson BA, Duncan SR, Ohori NP, et al. Recurrence of sarcoidosis in pulmonary allograft recipients. Am Rev Respir Dis 1993; 148: 1373-1377.
73. Heatly T, Sekela M, Berger R. Single lung transplantation involving a donor with documented pulmonary sarcoidosis. J Heart Lung Transplant 1994; 13: 720-723.
74. Muller C, Briegel J, Haller M. et al. Sarcoidosis recurrence following lung transplantation. Transplantation 1996; 61: 1117-1119.
75. Anderson B, Sims K, Regnery R, et al. Detection of Rochalimaea henselae DNA in specimens from cat scratch disease patients by PCR. J Clin Microbiol 1994; 32: 942-948.
76. Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured bacillus of whipple's disease. N Engl J Med 1990; 327: 293-301.
77. Williams R, Nickerson D. Skin reactions in sarcoid. Proc Soc Exp Biol Med 1935; 33: 402-405.
78. Kveim A. En ny og spesifik kutan-reakjon ved Boecks sarcoid. (Preliminary report on new and specific cutaneous reaction in Boecks sarcoid.) Nord Med 1941; 9: 1969-1972.
79. Chase MW. The preparation and standardization of Kveim testing antigen. Am Rev Respir Dis 1961; 84: 86-88.
80. Siltzbach L. The Kveim test in sarcoidosis. JAMA 1961; 178: 476-482.
81. Lyons D, Donald S, Mitchell D, Asherson G. Chemical inactivation of the Kveim reagent. Respiration 1992; 59: 22-26.
82. Lindahl M, Andersson O, Ripe E. Holm G. Stimulation of bronchoalveolar lavage (BAL) and blood lymphocytes by Kveim antigen, tuberculin and concanavalin A in sarcoidosis. Br J Dis Chest 1988; 82: 386-393.
83. Mandell G, Sullivan G, Siltzbach L, Suratt P. In vitro culture of leukocytes from patients with sarcoidosis: in search of an "in vitro Kveim Test". Virchows Arch (Cell Pathol) 1981; 35: 201-205.
84. Reutgen H, Eckert H, Christ R. Der Kveimtest in der Sarkoidosediagnostik. (The Kveim test in the diagnosis of sarcoidosis.) Z Erkr Atmungsorgane 1988; 170: 306-313.
85. Ishioka S, Fujihara M, Takaishi M, Yamakido M, Hosoda Y. Anti-Kveim monoclonal antibody - new monoclonal antibody reacting to epithelioid cells in sarcoid granulomas. Chest 1990; 98: 1255-1258.
86. Zissel G, Richter E, Kataria YP, Homolka J, Schlaak M, Müller-Quernheim J. Analysis of the Kveim-Siltzbach-test-reagent for bacterial DNA. Sarcoidosis Vasc Diff Lung Dis 1997; 14: 15.
87. Rook GWA, Stanford JL. Slow bacterial infections or autoimmunity? Immunol Today 1992; 13: 160-164.
88. Müller-Quernheim J, Saltini C, Sondermeyer P, Crystal RG. Compartmentalized activation of the interleukin-2 gene by lung T-lymphocytes in active pulmonary sarcoidosis. J Immunol 1986; 137: 3475-3483.
89. Klein J, Horn T, Forman J, Silver R, Tierstein A, Moller D. Selection of oligoclonal Vβ-specific T cells in the intradermal response to Kveim-Siltzbach reagent in individuals with sarcoidosis. J Immunol 1995; 154: 1450-1460.
90. Cohn ZA, Fedorko ME, Hirsch JG, Morse SI, Siltzbach LE. The distribution of Kveim activity in subcellular fractions from sarcoid lymph nodes. In: Turiaf J, Chabot J, eds. Proceedings of the 4th International Conference on Sarcoidosis, La Sarkoidose. Paris, Masson & Co., 1976; pp. 141-149.
91. Armbruster C, Dekan G, Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust. Lancet 1996; 348: 690.
92. Segal BM, Klinman DM, Shevach EM. Microbial products induce autoimmune disease by an IL-12-dependent pathway. J Immunol 1997; 158: 5087-5090.
93. Mitchell DN, Scadding JN. Sarcoidosis. Am Rev Respir Dis 1974; 110: 774-802.
94. Konietzko N, Faupel-Bauer B, Kraft J. Die Atemwege bei Sarkoidose. Dtsch Med Wochenschr 1987; 112: 1772-1778.
95. Meier-Sydow J, Gebhardt T, Kronenberger H, et al. Diffuse pulmonary fibrosis with airflow obstruction - clinical entities and classification. Prax Klin Pneumol 1983; 37: 335-341.
96. Nowak D, Kanzow G, Magnussen H. Patienten mit Sarkoidose haben gehäuft eine bronchiale Hyperreaktivität. Pneumologie 1990; 44: 572-573.
97. Bechtel J, Starr T III, Dantzker D, Bower J. Airway hyperreactivity in patients with sarcoidosis. Am Rev Respir Dis 1981; 124: 759-761.
98. Cole S, Johnson K, Ward P. Pathology of sarcoidosis, granulomatous vasculitis, and other idiopathic granulomatous diseases of the lung. In: Fanburg B, ed. Sarcoidosis and Other Granulomatous Diseases of the Lung. Basel, Dekker, 1983; pp. 149-202.
99. Mitchell D, Scadding J, Heard B, Hinson K. Sarcoidosis: histopathological definition and clinical diagnosis. J Clin Pathol 1977; 30: 395-408.
100. Daly PD, O'Brian DS, Robinson I, Prichard JS. Hodgkin's disease with a granulomatous pulmonary presentation mimicking sarcoidosis. Thorax 1988; 43: 407-409.
101. du Bois RM. Mimics of sarcoidosis, extrinsic allergic alveolitis. Sarcoidosis 1991; 8: 85-88.
102. James DG. Mimics of sarcoidosis, oro-facial granulomatosis (Melkersson-Rosenthal Syndrome). Sarcoidosis 1991; 8: 84.
103. Brincker H. The sarcoidosis-lymphoma syndrome. Br J Cancer 1986; 54: 467-473.
104. Newman LS, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992; 145: 1212-1214.
105. Müller-Quernheim J, Zissel G, Schopf R, Vollmer E, Schlaak M. Differentialdiagnose Berylliose/Sarkoidose bei einem Zahntechniker. Dtsch Med Wochenschr 1996; 121: 1462-1466.
106. Kent DC, Houk VN, Elliott RC, Sokolowski JW, Baker JH, Sorensen K. The definitive evaluation of sarcoidosis. Am Rev Respir Dis 1970; 101: 721-727.
107. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment of sarcoidosis. Am J Respir Crit Care Med 1994; 149: 893-898.
108. Sones M, Israel H. Course and prognosis of sarcoidosis. Am J Med 1960; 29: 84-93.
109. Stone D, Schwartz A. A long term study of sarcoid and its modification by steroid therapy. Lung function and other factors of prognosis. Am J Med 1966; 41: 528-540.
110. Car BD, Meloni F, Luisetti M, Semenzato G, Gialdroni-Grassi G, Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 1994; 149: 655-659.
111. Standiford T, Rolfe M, Kunkel S, et al. Macrophage inflammatory protein-1α expression in interstitial lung disease. J Immunol 1993; 151: 2852-2863.
112. Ming JW, Bersani L, Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol 1987; 138: 1469-1474.
113. Kiemle-Kallee J, Kreipe H, Radzun HJ, et al. Alveolar macrophages in idiopathic pulmonary fibrosis display a more monocyte-like immunophenotype and an increased release of free oxygen radicals. Eur Respir J 1991; 4: 400-406.
114. Striz I, Wang J, Teschler H, Sorg C, Costabel U. Phenotypic markers of alveolar macrophage maturation in pulmonary sarcoidosis. Lung 1993; 171: 293-303.
115. Pforte A, Gerth C, Voss A, et al. Proliferating alveolar macrophages in BAL and lung function changes in interstitial lung. Eur Respir J 1993; 6: 951-955.
116. Petrek M, Pantelidis P, Southcott AM, et al. The source and role of RANTES in interstitial lung disease. Eur Respir J 1997; 10: 1207-1216.
117. Hunninghake GW. Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis. Am Rev Respir Dis 1984; 129: 569-572.
118. Müller-Quernheim J, Pfeifer S, Männel D, Strausz J, Ferlinz R. Lung restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am Rev Respir Dis 1992; 145: 187-192.
119. Strausz J, Männel D, Pfeifer S, Borkowski A, Ferlinz R, Müller-Quernheim J. Spontaneous monokine release by alveolar macrophages in chronic sarcoidosis. Int Archs Allergy Appl Immun 1991; 96: 68-75.
120. Homolka J, Müller-Quernheim J. Increased interleukin 6 production by bronchoalveolar lavage cells in patients with active sarcoidosis. Lung 1993; 171: 173-183.
121. Steffen M, Petersen J, Oldigs M, et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. Chest 1993; 91: 939-949.
122. Kunkel SL, Remick DG, Strieter RM, Larrick JW. Mechanisms that regulate the production and effects of tumor necrosis factor-α. Crit Rev Immunol 1989; 9: 93-117.
123. 2 and leukotriene B4 by alveolar macrophages from patients with sarcoidosis. Thorax 1997; 52: 76-83.
124. Foley N, Lambert C, McNicol M, Johnson N, Rook GAW. An inhibitor of the toxicity of tumor necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease. Clin Exp Immunol 1990; 80: 395-399.
125. Seckinger P, Zhang JH, Hauptmann B, Dayer JM. Characterisation of tumor necrosis factor-α (TNF-α) inhibitor. Evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990; 87: 5188-5192.
126. Walker C, Bauer W, Braun R, et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994; 150: 1038-1048.
127. Nakayama T, Hashimoto E, Amemiya E, Horie T. Elevation of plasma-soluble tumor necrosis factor receptors (TNF-R) in sarcoidosis. Clin Exp Immunol 1997; 104: 318-324.
128. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379-385.
129. Lem VM, Lipscomb MF, Weissler JC, et al. Bronchoalveolar cells from sarcoid patients demonstrate enhanced antigen presentation. J Immunol 1985; 135: 1766-1771.
130. Venet A, Hance AJ, Saltini C, Robinson BWS, Crystal RG. Enhanced alveolar macrophage-mediated antigen-induced T lymphocyte proliferation in sarcoidosis. J Clin Invest 1985; 75: 293-301.
131. Zissel G, Ernst M, Schlaak M, Müller-Quernheim J. Accessory function of alveolar macrophages from patients with sarcoidosis and other granulomatous and non-granulomatous lung diseases. J Invest Med 1997; 45: 75-86.
132. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992; 360: 266-268.
133. Zissel G, Aulitzky W, Lorenz J, Huber C, Müller-Quernheim J. Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol Immun 1996; 42: 122-126.
134. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996; 335: 1369-1377.
135. Costabel U, Bross KJ, Rühle KH, Lohr GW, Matthys H. Ia-like antigens on T-cells and their subpopulations in pulmonary sarcoidosis and hypersensitivity pneumonitis. Am Rev Respir Dis 1985; 131: 337-342.
136. Saltini C, Hemler ME, Crystal RG. T lymphocytes compartmentalized on the epithelial surface of the lower respiratory tract express the very late activation antigen complex VLA-1. Clin Immunol Immunopathol 1988; 46: 221-233.
137. Müller-Quernheim J, Krönke M, Strausz J, Schykowski M, Ferlinz R. Interleukin-2 receptor gene expression by bronchoalveolar lavage lymphocytes in pulmonary sarcoidosis. Am Rev Respir Dis 1989; 140: 82-88.
138. duBois RM, Kirby M, Balbi B, Saltini C, Crystal RG. T-lymphocytes that accumulate in the lung in sarcoidosis have evidence of recent stimulation of the T-cell antigen receptor. Am Rev Respir Dis 1992; 145: 1205-1211.
139. Kita S, Tsuda T, Sugisaki K, Miyazaki E, Matsumoto T. Characterization of distribution of T lymphocyte subsets and activated T lymphocytes infiltrating into sarcoid lesions. Intern Med 1995; 34: 847-855.
140. Modlin RL, Hofman FM, Meyer PR, Sharma OP, Taylor CR, Rea TH. In situ demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis. Clin Exp Immunol 1983; 51: 430-438.
141. Pinkston P, Bitterman PB, Crystal RG. Spontaneous release of interleukin-2 by lung T-lymphocytes in active pulmonary sarcoidosis. N Engl J Med 1983; 308: 793-800.
142. Hunninghake GW, Bedell GN, Zavala DC, Monick M, Brady M. Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis. Am Rev Respir Dis 1983; 128: 634-636.
143. Devergne O, Emilie D, Peuchmaur M, Crevon MC, D'Agay MF, Galanaud P. Production of cytokines in sarcoid lymph nodes: preferential expression of interleukin-1β and interferon-γ genes. Hum Pathol 1992; 23: 317-323.
144. Asano M, Minagawa T, Ohmichi M, Hiraga Y. Detection of endogenous cytokines in sera or in lymph nodes obtained from patients with sarcoidosis. Clin Exp Immunol 1991; 84: 92-96.
145. Saltini C, Spurzem JR, Lee JJ, Pinkston P, Crystal RG. Spontaneous release of interleukin-2 by lung T-lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+ DR+ T-cell subset. J Clin Invest 1986; 77: 1962-1970.
146. Paine RI, Mody CH, Chawis A, Spahr MA, Turka LA, Toews GB. Alveolar epithelial cells block lymphocyte proliferation in vitro without inhibiting activation. Am J Respir Cell Mol Biol 1991; 5: 221-229.
147. Strauchen JA, Breakstone BA. IL-2 receptor expression in human lymphoid lesions. Am J Pathol 1987; 126: 506-512.
148. Holter J, Park H, Sjoerdsma K, Kataria Y. Nonviable autologous bronchoalveolar lavage cell preparations induce intradermal epithelioid cell granulomas in sarcoidosis patients. Am Rev Respir Dis 1992; 145: 864-871.
149. Moller DR, Konishi K, Kirby M, Balbi B, Crystal RG. Bias toward use of a specific T-cell receptor β-chain variable region in a subgroup of individuals with sarcoidosis. J Clin Invest 1988; 82: 1183-1191.
150. Grunewald J, Olerup O, Persson U, Öhrn BM, Wigzell H, Eklund A. T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc Natl Acad Sci USA 1994; 91: 4965-4969.
151. Forman J, Klein J, Silver R, Liu M, Greenlee B, Moller D. Selective activation and accumulation of oligoclonal Vβ-specific T cells in active pulmonary sarcoidosis. J Clin Invest 1994; 94: 1533-1542.
152. Tamura N, Moller D, Balbi B, Crystal R. Preferential usage of the T-cell antigen receptor beta-chain constant region C beta 1 element by lung T-lymphocytes of patients with pulmonary sarcoidosis. Am Rev Respir Dis 1991; 143: 635-639.
153. Zissel G, Bäumer I, Fleischer B, Schlaak M, Müller-Quernheim J. TCR V beta families in T cell clones from sarcoid lung parenchyma, BAL and blood. Am J Respir Crit Care Med 1997; 156: 1593-1600.
154. Bellocq A, Lecossier D, Pierre-Audigier C, Tazi A, Valeyre D, Hance AJ. T cell receptor repertoire of T lymphocytes recovered from the lung and blood of patients with sarcoidosis. Am J Respir Crit Care Med 1994; 149: 646-654.
155. Dohi M, Yamamoto K, Masuko K, et al. Accumulation of multiple T cell clonotypes in lungs of healthy individuals and patients with pulmonary sarcoidosis. J Immunol 1994; 152: 1983-1988.
156. Silver RF, Crystal RG, Moller DR. Limited heterogeneity of biased T-cell receptor Vβ gene usage in lung but not blood T cells in active pulmonary sarcoidosis. Immunology 1996; 88: 516-523.
157. Gorski J, Vassal M, Zhu X, Kissella B, Keevr C, Flomenbera N. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. J Immunol 1994; 152: 5109-5119.
158. Burastero SE, Borgonovo B, Gaffi D, et al. The repertoire of T-lymphocytes recovered by bronchoalveolar lavage from healthy nonsmokers. Eur Respir J 1996; 9: 319-327.
159. Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989; 320: 1103-1109.
160. Wahlström J, Berlin M, Lundgren R, et al. Lung and blood T-cell receptor repertoire in extrinsic allergic alveolitis Eur Respir J 1997; 10: 772-779.
161. Grunewald J, Hultman T, Bucht A, Eklund A, Wigzell H. Restricted usage of T cell receptor V alpha/J alpha gene segments with different nucleotide but identical amino acid sequences in HLA-DR3+ sarcoidosis patients. Mol Med 1995; 1: 287-296.
162. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
163. Fiorentino DF, Zlotniu A, Mosmann TR, Howard M. O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815-3822.
164. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996; 80: 225-235.
165. Robinson BWS, McLemore T, Crystal RG. γ-Interferon is spontaneously released by alveolar macrophages and lung T-lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985; 75: 1488-1495.
166. Hoshino T, Itoh K, Gouhara R, et al. Spontaneous production of various cytokines except IL4 from CD4+ T cells in the affected organs of sarcoidosis patients. Clin Exp Immunol 1995; 102: 399-405.
167. Minshall EM, Tsicopoulos A, Yasruel Z, et al. Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis. Eur Respir J 1997; 10: 2034-2039.
168. Bäumer I, Zissel G, Schlaak M, Müller-Quernheim J. Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1997; 16: 171-177.
169. Grutters JC, Drent M, van Velzen-Blad H, van den Bosch JMM. Improvement of bronchial asthma during an episode of active sarcoidosis. A case report. Am J Respir Crit Care Med 1996; 153: A282.
170. Balbi B, Moller DR, Kirby M, Holrody KJ, Crystal RG. Increased numbers of T-lymphocytes with γδ-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis. J Clin Invest 1990; 85: 1353-1361.
171. Pfeifer S, Müller-Quernheim J. Subtypisierung von T-Lymphozyten bei Sarkoidose. Pneumologie 1994; 48: 427-432.
172. Raulf M, Liebers V, Steppert C, Baur X. Increased γ/δ-positive T-cells in blood and bronchoalveolar lavage of patients with sarcoidosis and hypersensitivity pneumonitis. Eur Respir J 1994; 7: 140-147.
173. Balbi B, Valle M, Oddera S, et al. T-lymphocytes with γδ+ Vδ2+ antigen receptors are present in increased proportions in a fraction of patients with tuberculosis or with sarcoidosis. Am Rev Respir Dis 1993; 148: 1685-1690.
174. Forrester J, Newman L, Wang Y, King T, Kotzin B. Clonal expansion of lung Vδ1+ cells in pulmonary sarcoidosis. J Clin Invest 1993; 91: 292-300.
175. Tazi A, Fajac I, Soler P, Valeyre D, Battesti JP, Hance AJ. γ/δ T-lymphocytes are not increased in number in granulomatous lesions of patients with tuberculosis or sarcoidosis. Am Rev Respir Dis 1991; 144: 1373-1376.
176. Jenkins R, Nikaein A, Zimmermann A, Meek A, Lipsky P. T cell receptor Vβ gene bias in rheumatoid arthritis. J Clin Invest 1993; 92: 2688-2701.
177. Posnett DN, Schmelkin I, Burton DA, August A, McGrath H, Mayer LF. T cell antigen receptor V gene usage. Increases in Vβ8+ T-cells in Crohn's disease. J Clin Invest 1990; 85: 1770-1776.
178. Newman LS. To Be2+ or not to Be2+: immunogenetics and occupational exposure (Comment). Science 1993; 262: 197-198.
179. Kubicka-Mulanyi M, Kremer J, Rottmann N, et al. Murine systemic autoimmune disease induced by mercuric chloride: T helper cells reacting to self proteins. Int Arch Allergy Immunol 1996; 109: 11-20.
180. Kubicka-Muranyi M, Griem P, Lübben B, Rottmann N, Lührmann R, Gleichmann E. Mercuric-chloride-induced autoimmunity in mice involves up-regulated presentation by spleen cells of altered and unaltered nucleolar self antigen. Int Arch Allergy Immunol 1995; 108: 1-10.
181. Kunkel SL, Chensue SW, Strieter RM, Lynch JP, Remick DG. Cellular and molecular aspects of granulomatous inflammation. Am J Respir Cell Mol Biol 1989; 1: 439-447.
182. Subramanian G, Kazura JW, Pearlman E, Jia X, Malhtra I, King CL. B7-2 requirement for helminth-induced granuloma formation and CD4 Type 2 T helper cell cytokine expression. J Immunol 1997; 158: 5914-5920.
183. Singh RP, Patarca R, Schwartz J, Singh P, Cantor H. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med 1990; 171: 1931-1942.
184. Nau GJ, Guilfoile P, Chupp GL, et al. A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis. Proc Natl Acad Sci USA 1997; 94: 6414-6419.
185. Chensue SW, Otterness IG, Higashi GI, Shmyr Forsch C, Kunkel SL. Monokine production by hypersensitivity (Shistosoma mansoni egg) and foreign body (Sephadex bead)-type granuloma macrophages. Evidence for sequential production of IL-1 and tumor necrosis factor. J Immunol 1989; 142: 1281-1286.
186. Kindler V, Sappino A, Grau G, Piguet P, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-740.
187. Gudmundsson G, Hunninghake GW. Interferon-γ is necessary for the expression of hypersensitivity pneumonitis. J Clin Invest 1997; 99: 2386-2390.
188. Kemp M, Theander TG, Kharazmi A. The contrasting roles of CD4+ T cells in the intracellular infections in humans: leishmaniasis as an example. Immunol Today 1996; 17: 13-16.
189. Chensue SW, Warmington K, Ruth JH, Lukacs N, Kunkel SL. Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice: analysis of local and regional cytokine and chemokine networks. J Immunol 1997; 159: 356-573.
190. Bergeron A, Bonay M, Kambouchner M, et al. Cytokine patterns in tuberculous and sarcoid granulomas: correlations with histopathologic features of the granulomatous response. J Immunol 1997; 159: 303-443.
191. Smith RE, Strieter RM, Zhang K, Phan SH, Standiford TJ, Lukacs NW. A role for C-C chemokines in fibrotic lung disease. J Leukoc Biol 1995; 57: 782-787.
192. Rolfe MW, Kunkel SL, Standiford TJ, et al. Pulmonary fibroblast expression of interleukin-8: a model for alveolar macrophage-derived cytokine networking. Am J Respir Cell Mol Biol 1991; 5: 493-501.
193. Moseley PL, Hemken C, Monick MM, Nugent KM, Hunninghake GW. Interferon and growth factor activity for human lung fibroblasts: release from
194. Bjermer L, Eklund A, Blaschke E. Bronchoalveolar lavage fibronectin in patients with sarcoidosis: correlation to hyaluronan and disease activity. Eur Respir J 1991; 4: 965-971.
195. Mornex JF, Leroux C, Greenland T, Ecochard D. From granuloma to fibrosis in interstitial lung disease: molecular and cellular interactions. Eur Respir J 1994; 7: 779-785.
196. Pohl WR, Thompson AB, Köhn H, et al. Serum procollagen III peptide levels in subjects with sarcoidosis. A 5-year follow-up study. Am Rev Respir Dis 1992; 145: 412-417.
197. O'Connor CM, Ward K, van Breda A, McIlgorm A, Fitz-Gerald MX. Type 3 procollagen peptide in bronchoalveolar lavage fluid. Poor indicator of course and prognosis in sarcoidosis. Chest 1989; 96: 339-344.
198. Perez RL, Duncan A, Hunter RL, Staton GL. Elevated D dimer in the lungs and blood of patients with sarcoidosis. Chest 1993; 103: 1100-1106.
199. Schaberg T, Orzechowski K, Oesterling C, Lode H, Schuppan D. Simultaneous measurement of collagen type-VI-related antigen and procollagen type-N-propeptide levels in bronchoalveolar lavage. Eur Respir J 1994; 7: 1221-1226.
200. Bensadoun ES, Burke AK, Hogg JC, Roberts CR. Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med 1996; 154: 1819-1828.
201. Lammi L, Kinnula V, Lahde S, et al. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Eur Respir J 1997; 10: 2725-2730.
202. Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156: 4952-4960.
203. Pinkston P, Saltini C, Müller-Quernheim J, Crystal RG. Corticosteroid therapy suppresses spontaneous interleukin-2 release and spontaneous proliferation of lung T-lymphocytes of patients with active pulmonary sarcoidosis. J Immunol 1987; 139: 755-760.
204. Center DM, Kornfeld H, Cruikshank WW. Interleukin 16 and its function as a CD4 ligand. Immunol Today 1996; 17: 476-481.
205. Gaede KI, Zissel G, Schwulera U, et al. Spontaneous and interleukin-2-modulated cytokine release of bronchoalveolar cells in pulmonary malignancy. Eur Cytokine Netw 1997; 8: 395-400.
206. Müller-Quernheim J, Pfeifer S, Kienast K, Zissel G. Spontaneous interleukin-2 release of bronchoalveolar lavage cells in sarcoidosis is a co-determinator of prognosis. Lung 1996: 174: 243-253.
207. Girgis R, Basha M, Maliarik M, Popovich J Jr, Iannuzzi M. Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis. Am J Respir Crit Care Med 1995; 152: 71-75.
208. Takizawa H, Satoh M, Okazaki H, et al. Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin Exp Immunol 1997; 107: 175-181.
209. Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Müller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Invest Med 1998; 46: 223-231.
210. Otte HG, Hartig C, Stadler R. Sarkoidose bei Interferon-alpha-Therapie. (Sarcoidosis in interferon-alpha therapy.) Hautarzt 1997; 48: 482-487.
211. Bansal AS, Bruce J, Hogan PG, Allen RK. An assessment of peripheral immunity in patients with sarcoidosis using measurements of serum vitamin D3, cytokines and soluble CD23. Clin Exp Immunol 1997; 110: 92-97.
212. Prior C, Knight RA, Herold M, Ott G, Spiteri MA. Pulmonary sarcoidosis: patterns of cytokine release in vitro. Eur Respir J 1996; 9: 47-53.
213. Prior C, Haslam P. Increased levels of serum interferon-γ in pulmonary sarcoidosis and relationship with response to corticosteroid therapy. Am Rev Respir Dis 1991; 143: 53-60.
214. Swider C, Laba A, Moniewska A, Gerdes J, Flad HD, Lange A. Presence of mRNA for interferon-gamma (IFN-gamma) in blood mononuclear cells is associated with an active stage I sarcoidosis. Clin Exp Immunol 1995; 100: 401-405.
215. Westermann J, Persin S, Matyas J, van der Meide P, Pabst R. Migration of so-called naive and memory T lymphocytes from blood to lymph in the rat. The influence of IFN-gamma on the circulation pattern. J Immunol 1994; 152: 1744-1750.
216. Westermann J, Pabst R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today 1990; 11: 406-410.
217. Sugiyama Y, Kasahara T, Mukaida N, Matsushima K, Kitamura S. Chemokines in bronchoalveolar lavage fluid in summer-type hypersensitivity pneumonitis. Eur Respir J 1995; 8: 1084-1090.
218. Iida K, Kadota J, Kawakami K, Matsubara Y, Shirai R, Kohno S. Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis. Thorax 1997; 52: 431-437.
219. Keane MP, Arenberg DA, Lynch JPr, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159: 1437-1443.
220. Bäumer I, Zissel G, Schlaak M, Müller-Quernheim J. Soluble intercellular adhesion molecule 1 (sICAM-1) in bronchoalveolar lavage (BAL) cell cultures and in the circulation of patients with tuberculosis, hypersensitivity pneumonitis and sarcoidosis. Eur J Med Res 1998, 3: 288-294.
221. Müller-Quernheim J, Pfeifer S, Strausz J, Ferlinz R. Correlation of clinical and immunological parameters of the inflammatory activity of pulmonary sarcoidosis. Am Rev Respir Dis 1991; 144: 1322-1329.
222. Guede KI, Fitschen J, Ernst M, Schlaan M, Müller-Quernheim J. Expression and shedding of tumor necrosis factor receptors in bronchoalveolar cells. Am J Respir Crit Care Med 1998; 157: A436.
223. Nakayama T, Hashimoto S, Amemiya E, Horie T. Elevation of plasma-soluble tumour necrosis factor receptors (TNF-R) in sarcoidosis. Clin Exp Immunol 1996; 104: 318-324.
224. Bäumer I, Zissel G, Schlaak M, Müller-Quernheim J. Shed sICAM-1 molecules in BAL cell supernatants and serum of patients with pulmonary sarcoidosis. Lung 1997; 175: 105-116.
225. Pforte A, Schiessler A, Kressenstein S, et al. ICAM-1 expression on alveolar macrophages and in serum of sarcoidosis patients. J Clin Lab Immunol 1995; 46: 125-135.
226. Ziegenhagen MW, Fitschen J, Martinet N, Schlaan M, Müller-Quernheim J. Serum level of soluble tumor necrosis factor Type II reflects disease activity in sarcoidosis. Am J Respir Crit Care Med 1998; 157: A29.
227. Shijubo N, Imai K, Shigehara K, et al. Soluble intercellular adhesion molecule-1 (ICAM1) in sera and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Clin Exp Immunol 1994; 95: 156-161.
228. Valeyre D, Soler P, Basset G, et al. Glucose, K+, and albumin concentrations in the alveolar milieu of normal humans and pulmonary sarcoidosis patients. Am Rev Respir Dis 1991; 143: 1096-1101.
229. Planès C, Valeyre D, Loiseau A, Bernaudin J, Soler P. Ultrastructural alterations of the air-blood barrier in sarcoidosis and hypersensitivity pneumonitis and their relation to lung histopathology. Am J Respir Crit Care Med 1994; 150: 1067-1074.
230. Rothlein R, Mainolfi E, Czajkowski M, Marlin S. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147: 3788-3793.
231. Berghella AM, Pellegrini P, Del Beato T, et al. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immunol Immunother 1998; 45: 241-249.
232. Piguet P, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7: 515-518.
233. Kline JN, Schwartz D, Monick MM, Floerchinger CS, Hunninghake GW. Relative release of interleukin-1b and interleukin-1 receptor antagonist by alveolar macrophages. A study in asbestos-induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis. Chest 1993; 104: 47-53.
234. Rolfe MW, Standiford TJ, Kunkel SL, et al. Interleukin-1 receptor antagonist expression in sarcoidosis. Am Rev Respir Dis 1993; 148: 1378-1384.
235. Ulich TR, Yin SM, Guo KZ, del Castillo J, Eisenberg SP, Thompson RC. The intratracheal administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation.Am J Pathol 1991; 138: 521-524.
236. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101: 311-320.
237. deWaal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915-924.
238. Zissel G, Homolka J, Schlaak J, Schlaak M, Müller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996; 154: 713-719.
239. Wahl SM, McCartney-Francis N, Mergenhagen S. Inflammatory and immunoregulatory roles of TGF-β. Immunol Today 1989; 10: 258-261.
240. Schmitt E, Höhn P, Hüls C, et al. T helper type 1 development of native CD4+ T cells requires the coordinate action of interleukin-12 and interferon-γ and is inhibited by transforming growth factor-β. Eur J Immunol 1994; 24: 793-798.
241. Koberda J, Grimm E, Moser R. Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor β inhibition of lymphokine-activated killer cell generation. J Cancer Res Clin Oncol 1993; 119: 131-136.
242. Begovich AB, Klitz W, Moonsamy PV, Van de Water J, Peltz G, Gershwin ME. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens 1994; 43: 71-77.
243. Begovich AB, Helmuth RC, Oksenberg JR, et al. HLA-DP beta and susceptibility to multiple sclerosis: an analysis of caucasoid and Japanese patient populations. Hum Immunol 1990; 28: 365-372.
244. Lenhart K, Kolek V, Bartova A. HLA antigens associated with sarcoidosis. Dis Markers 1990; 8: 23-29.
245. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997; 156: 1601-1605.
246. Grunewald J, Shigematsu M, Nagai S, Mikuniya T, Izumi T, Eklund A. T-cell receptor V gene expression in HLA-typed Japanese patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1995; 151: 151-156.
247. McGuire W, Hill A, Allsopp C, Greenwood B, Kwiatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-511.
248. Cabrera M, Shaw MA, Sharples C, et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995; 182: 1259-1264.
249. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1436-1439.
250. Stüber F, Petersen M, Bokelmann F, Schade F. A genomic polymorphism within the TNF locus influences TNF plasma levels and outcome of patients with severe sepsis. Crit Care Med 1995; 24: 381-384.
251. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199.
252. Seitzer U, Swider C, Stuber F, et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997; 9: 787-790.
253. Hino T, Nakamura H, Shibata Y, Abe S, Kato S, Tomoike H. Elevated levels of type II soluble tumor necrosis factor receptors in the bronchoalveolar lavage fluids of patients with sarcoidosis. Lung 1997; 175: 187-193.
254. Agostini C, Zambello R, Sancetta R, et al. Expression of tumor necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease. Am J Respir Crit Care Med 1996; 153: 1359-1367.
255. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177: 557-560.
256. Cox A, Gonzalez AM, Wilson AG, et al. Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. Diabetologia 1994; 37: 500-503.
257. Wilson AG, Gordon C, di Giovine FS, et al. A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 1994; 24: 191-195.
258. Ishihara M, Ohno S, Ishida T, et al. Molecular genetic studies of class II alleles in sarcoidosis. Tissue Antigens 1994; 43: 238-241.
259. Gill RG, Babcock SK, Lafferty KJ. A quantitative analysis of antigen-triggered lymphokine production by activated T cells. J Immunol 1987; 138: 1130-1136.
260. Suzuki K, Tamura N, Iwase A, Dambara T, Kira S. Prognostic value of Ia+ T lymphocytes in bronchoalveolar lavage fluid in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996; 154: 707-712.
261. Drent M, van Velzen-Blad H, Diamant M, Hoogsteden HC, van den Bosch JMM. Relationship between presentation of sarcoidosis and T lymphocyte profile. A study in bronchoalveolar lavage fluid. Chest 1993; 104: 795-800.
262. Ward K, O'Connor C, Odlum C, Fitzgerald MX. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax 1989; 44: 6-12.
263. Verstraeten A, Demedts M, Verwilghen J, et al. Predictive value of bronchoalveolar lavage in pulmonary sarcoidosis. Chest 1990; 98: 560-567.
264. Foley NM, Coral AP, Tung K, Hudspith BN, James DG, Johnson NMI. Bronchoalveolar lavage cell counts as predictor of short term outcome in pulmonary sarcoidosis. Thorax 1989; 44: 732-738.
265. Lin YH, Haslam PL, Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. Thorax 1985; 40: 501-507.
266. Hollinger WM, Staton GW, Fajman WA, Gilman MJ, Pine JR, Check LJ. Prediction of therapeutic response in steroid-treated pulmonary sarcoidosis. Am Rev Respir Dis 1985; 132: 65-69.
267. Buchalter S, App W, Jackson L, Chandler D, Jackson R, Fulmer J. Bronchoalveolar lavage cell analysis in sarcoidosis. A comparison of lymphocyte counts and clinical course. Ann NY Acad Sci 1986; 465: 678-684.
268. Lavoilette M, La Forge J, Tennina S, Boulet L. Prognostic value of lavage lymphocyte count in recently diagnosed pulmonary sarcoidosis. Chest 1991; 100: 380-384.
269. 2 release, alveolitis, and disease severity in sarcoidosis. Chest 1993; 103: 832-838.
270. Ainslie GM, Poulter LW, du Bois RM. Relation between immunocytological features of bronchoalveolar lavage fluid and clinical indices in sarcoidosis. Thorax 1989; 44: 501-509.
271. Prior C, Barbee RA, Evans PM, et al. Lavage versus serum measurement of lysozyme, angiotensin converting enzyme and other inflammatory markers in sarcoidosis. Eur Respir J 1990; 3: 1146-1154.
272. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin: release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310-316.
273. Eklund A, Blaschke E. Elevated serum neopterin in sarcoidosis. Lung 1986; 164: 325-332.
274. Prior C, Frank A, Fuchs D, et al. Urinary neopterin excretion in pulmonary sarcoidosis: correlation to clinical course of disease. Clin Chim Acta 1988; 177: 211-220.
275. Homolka J, Lorenz J, Zuchhold HD, Müller-Quernheim J. Evaluation of soluble CD14 and serum neopterin as serum parameters of inflammatory activity of pulmonary sarcoidosis. Clin Invest 1992; 70: 909-916.
276. Meliconi R, Lalli E, Borzi R, et al. Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome. Thorax 1990; 45: 536-540.
277. Taylor A. Serum adenosine deaminase activity is increased in sarcoidosis. Clin Chem 1984; 30: 499-500.
278. Lorenz J, Wetzel E, Müller-Quernheim J, Ferlinz R. Adenosin deaminase: a novel serum marker of disease activity in sarcoidosis. Am Rev Respir Dis 1994; 149: A609.
279. Hol BEA, Hintzen RQ, van Lier RAW, Alberts C, Out TA, Jansen HM. Soluble and cellular markers of T cell activation in patients with pulmonary sarcoidosis. Am Rev Respir Dis 1993; 148: 643-649.
280. Semenzato G, Cipriani A, Trentin L, et al. High serum levels of soluble interleukin-2 receptors in sarcoidosis. Sarcoidosis 1987; 4: 25-27.
281. Lawrence EC, Brousseau KP, Berger MB, Kurman CC, Marcon L, Nelson DL. Elevated concentration of soluble interleukin-2 receptors in serum samples and bronchoalveolar fluids in active sarcoidosis. Am Rev Respir Dis 1988; 137: 759-764.
282. Ina Y, Takada K, Sato T, Yamamoto M, Noda M, Morishita M. Soluble interleukin 2 receptor in patients with sarcoidosis. Possible origin. Chest 1992; 102: 1112-1133.
283. Pforte A, Brunner A, Gais P, et al. Concomitant modulation of serum-soluble interleukin-2 receptor and alveolar macrophage interleukin-2 receptor in sarcoidosis. Am Rev Respir Dis 1993; 147: 717-722.
284. DeRemee R. The present status of treatment of pulmonary sarcoidosis: a house divided. Chest 1977; 71: 388-393.
285. Israel H, Fouts D, Beggs R. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973; 107: 609-614.
286. Zaki MH, Lyons HA, Leilop L, Huang CT. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. NY State J Med 1987; 87: 496-499.
287. Gibson G, Prescott R, Muers M, et al. British Thoracic Society sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51: 238-247.
288. Lynch JPr, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155: 395-420.
289. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155: 846-851.
290. Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am J Respir Crit Care Med 1997; 156: 1371-1376.
291. Lynch JPr. Pulmonary sarcoidosis: current concepts and controversies. Compr Ther 1997; 23: 197-210.
292. Baughman RP, Lower EE. Steroid-sparing alternative treatments for sarcoidosis. Clin Chest Med 1997; 18: 853-864.
293. Martinet Y, Pinkston P, Saltini C, Spurzem J, Müller-Quernheim J, Crystal RG. Evaluation of the in vitro and in vivo effects of cyclosporine on the T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis 1988; 138: 1242-1248.
294. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990; 142: 1268-1271.
295. Gupta M, Satyaraj E, Durdik JM, Rath S, Bal V. Differential regulation of T cell activation for primary versus secondary proliferate responses. J Immunol 1997; 158: 4113-4121.
296. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391-394.
297. Zabel P, Wolter D, Schönharting M, Schade U. Oxpentifylline in endotoxinaemia. Lancet 1989; 334: 1474-1477.
298. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Karp CL. Inhibition of human interleukin-12 production by pentoxifylline. Immunology 1997; 91: 197-203.
299. Funk J, Ernst M, Schlaak M, Zabel P. Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporine. Int J Immunopharmacol 1995; 17: 1007-1016.
300. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-1669.
301. Sheskin J. Further observation with thalidomide in lepra reactions. Lepr Rev 1965; 36: 183-187.
302. Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159: 5157-5161.
303. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
304. Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw RJ. Thalidomide reduces tumor necrosis factor-α production by human alveolar macrophages. Respir Med 1997; 91: 31-40.
305. Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ. The genetics of psoriasis. Arch Dermatol 1994; 130: 216-224.